EGFR and non-small cell lung carcinoma: The ORIENT-31 trial demonstrated that the combination of immunotherapy with chemotherapy significantly improved the clinical outcomes compared with chemotherapy alone among previously treated EGFR-mutation NSCLC (Lu et al., 2022).